Privacy Policy

Online Privacy Policy

Effective Date: September 13, 2022

We at Osmotica Pharmaceuticals, LLC, along with our subsidiaries and affiliates (collectively, “Osmotica”), respect your concerns about privacy. Osmotica operates one or more websites (collectively, the “Osmotica Websites”)

This Privacy Notice describes the types of information we collect about consumers, how we collect and may use that information, and with whom we share it. It also describes the measures we take to protect your personal information. This

Privacy Notice describes Osmotica’s policies and procedures and is not a contract between you and Osmotica that creates any rights or obligations.

Information We Obtain

The types of information we may obtain about consumers include:

  • Information that consumers provide to Osmotica that is necessary to fulfill the purpose of the visitor’s interaction with Osmotica, such as user names and email addresses for those who sign up for a newsletter or other resources
  • Financial information necessary to complete certain transactions
  • Other personal information you may provide to us to obtain a Osmotica service or product

In addition, when you visit our websites, we may collect certain information by automated means, such as cookies or web beacons, which may include Internet Protocol addresses, unique device identifiers, browser characteristics, device characteristics, operating systems, language preferences, referring URL’s, information on actions taken, and dates and times of activity. We may also obtain information about you from our resellers or other third-party partners or acquire information from public sources or from third-party sources, such as our advertising and market research partners.

How We Use the Information We Obtain

Osmotica collects consumer information only insofar as is necessary or appropriate to fulfill the purpose of the consumer’s interaction with Osmotica. Osmotica does not use or disclose personally-identifying information other than as described below.

We may use the information for the following purposes:

  • Send you news, updates, promotions, product information, event announcements, and other marketing communications.
  • Disclose logged in user and commenter IP addresses under the same circumstances that it uses and discloses personally-identifying information as described below, except that blog commenter IP addresses are visible and disclosed to the administrators of the blog where the comment was left
  • Release non-personally-identifying information in the aggregate
  • Collect statistics about the behavior of visitors to its websites, such as monitoring popular blogs (but note that while Osmotica may display this information publicly or provide it to others, Osmotica does not disclose personally-identifying information other than as described herein)
  • Provide potentially personally-identifying information that Osmotica employees, contractors, and affiliated organization need to know in order to process it on Osmotica’s behalf or to provide services available at Osmotica’s websites. Such information is only provided to those that have agreed not to disclose it to others.

Additionally, Osmotica uses cookies to help Osmotica identify and track visitors, their usage of the Osmotica Websites, and their website access preferences. A cookie is a string of information that a website stores on a visitor’s computer, and that the visitor’s browser provides to the website each time the visitor returns. Osmotica visitors who do not wish to have cookies placed on their computers should set their browsers to refuse cookies before using the Osmotica Websites.

If you are a registered user of one or more Osmotica Websites and have supplied your email address, you agree that in addition to any Resources you may have solicited or requested, Osmotica may further send you an email to provide you with information, to inform you of new products, to solicit your feedback, or to keep you up to date on Osmotica and its products. If you send us a request (for example via a support email or via one of our feedback mechanisms), we reserve the right to publish it in order to help us clarify or respond to your request or to help us support other users.

Information We Share with Others

Osmotica does not sell personally-identifying information to anyone. Other than to its employees, contractors and affiliated organizations, as described above, Osmotica will disclose potentially personally-identifying and personally-identifying information only in response to a subpoena, court order or other governmental request, in response to an investigation, under process of law or when Osmotica believes in good faith that disclosure is reasonably necessary to protect Osmotica’s rights and interests, third parties, or the public at large. However, in the event (i) Osmotica engages in one more asset sales or purchases, (ii) Osmotica is acquired, (iii) Osmotica engages in one or more business combinations, mergers or acquisitions, (iv) substantially all of Osmotica’s assets are acquired, or (v) Osmotica is subject to an event bankruptcy, certain personally-identifying information such as user information may be deemed an asset of Osmotica and may subject to assignment, transfer and/or acquisition by a third party.


On our websites, we may use cookies to collect information about your online activities for use in providing you with advertising about products and services that are tailored to your individual interests. Advertisements appearing on any of the Osmotica websites may be delivered to users by advertising partners, who may set cookies. This Privacy Policy covers the use of cookies by Osmotica and does not cover the use of cookies by any advertisers.

How We Safeguard Your Personal Information

Osmotica takes administrative, technical, and physical safeguards to protect against the unauthorized access, use, alteration or destruction of potentially personally-identifying information.

Your Options

You have certain choices about how we communicate with you and what information we collect from you. You may choose not to receive marketing email communications from Osmotica by clicking the “Unsubscribe” link in our advertising emails.

If you have any questions or comments about this Privacy Notice, or if you are a California resident and would like to ask us to refrain from sharing your personal information with certain of our affiliates and other third parties for their marketing purposes, or to submit a data access or data deletion request, please contact us at: Email

Policy Changes

Osmotica may change this Policy from time to time and at any time, without notice, within the sole, independent, absolute and uncontrolled exercise of its discretion. Osmotica encourages visitors to frequently check this page for any changes to its Privacy Policy.

Brian Markison, Chairman of the Board and Chief Executive Officer

Brian Markison has served as Chairman of the Board and Chief Executive Officer of Osmotica since 2016. Mr. Markison is a healthcare industry veteran, with more than 30 years of operational, marketing, commercial development and sales experience with international pharmaceutical companies. He has served as an advisor to Avista Capital Partners since September 2012. He previously served as the President, Chief Executive Officer and board member of Fougera Pharmaceuticals, Inc., a dermatology-focused specialty pharmaceutical company sold to Sandoz Ltd., the generics division of Novartis AG. Before leading Fougera, Mr. Markison was Chairman and Chief Executive Officer of King Pharmaceuticals, Inc., which he joined as Chief Operating Officer in March 2004. He was promoted to President and Chief Executive Officer later that year and elected Chairman in 2007. Prior to joining King Pharmaceuticals, Inc., Mr. Markison held various senior leadership positions at Bristol-Myers Squibb. He serves as Chairman of the Board of Lantheus Holdings, Inc. and is on the board of directors of Avista Healthcare Public Acquisition Corp., National Spine and Pain Centers, LLC and Braeburn Pharmaceuticals, Inc. He is also a Director of the College of New Jersey.

James Schaub, Executive Vice President and Chief Operating Officer

James Schaub has served as our Executive Vice President and Chief Operating Officer since 2016. Mr. Schaub previously served as Chief Operating Officer of Trigen Laboratories and as Vice President of M&A at Fougera Pharmaceuticals, Inc. He also held several commercial roles of increasing responsibility at King Pharmaceuticals, Inc. Mr. Schaub is a graduate of Middlebury College and holds an M.B.A. from Rutgers Business School.

Andrew Einhorn, Chief Financial Officer

Andrew Einhorn joined as Chief Financial Officer in September 2017. Mr. Einhorn has more than 15 years of experience in the pharmaceutical industry. Mr. Einhorn previously served as the Chief Financial Officer of Edge Therapeutics, Inc., a clinical-stage biotechnology company that he joined as Executive Vice President of Corporate Development in 2013. Prior to that, he was a co-founder, Executive Vice President and Chief Financial Officer at Oceana Therapeutics, Inc. Previously, Mr. Einhorn was a co-founder and Chief Financial Officer of both Esprit Pharma, Inc. and ESP Pharma, Inc. Mr. Einhorn is licensed as a Certified Public Accountant in the State of New Jersey and holds a B.S. in Finance and Accounting from American University.

Christopher Klein, General Counsel and Secretary

Christopher Klein has served as our General Counsel and Secretary since December 2013. Mr. Klein previously served as the General Counsel of Fougera Pharmaceuticals, Inc. and as Deputy General Counsel at King Pharmaceuticals, Inc. Mr. Klein spent six years in senior legal roles with Bristol-Myers Squibb Company. Mr. Klein holds a B.A. in Biology from Adelphi University, an M.A. in Education from Columbia University and a J.D. from Fordham University.

Tina deVries, Ph.D., Executive Vice President, Research and Development

Tina deVries, Ph.D. became our Executive Vice President, Research & Development in May 2016. Dr. deVries most recently served as the Principal of TM deVries Consulting, LLC. She was previously Vice President of Nonclinical and Clinical Pharmacology at Actavis plc following its 2013 acquisition of Warner Chilcott plc where she served as the Vice President of Clinical Pharmacology. Dr. deVries holds a B.S. in Pharmacy and a Ph.D. in Pharmaceutics and Pharmaceutical Chemistry from The Ohio State University.

Lynn Palmer, Senior Vice President, Technical Operations

Lynn Palmer has served as our Senior Vice-President, Technical Operations since June 2017. Prior to that, he served as Vice-President, Manufacturing from February of 2016. Before Osmotica, Mr. Palmer served as Executive-Vice-President, Engineering at King Pharmaceuticals for six years. Previously Mr. Palmer led Engineering at Mallinckrodt Inc. (a division of Tyco Healthcare), and served as Vice-President, Production at Inbrand Corporation. Prior to Inbrand, he served in progressive manufacturing management roles at Kimberly-Clark Corporation from 1982-1996. Mr. Palmer holds a Bachelor of Applied Science in Paper Science and Engineering from Miami University.

Jarret Miller, Executive Vice President, Human Resources

Jarret Miller has served as our Executive Vice President, Human Resources since January 2016. Mr. Miller has more than 20 years of Human Resources experience in various roles of increasing responsibility. He previously served as the Head of Human Resources Operations and Services for the Americas at Teva Pharmaceuticals, Inc. Prior to that, he held the positions of Vice President, Human Resources at ConvaTec, Inc. and Senior Vice President, Human Resources at King Pharmaceuticals, Inc. Mr. Miller holds a B.S. in Statistics and Biometry from Cornell University.

David Burgstahler

David Burgstahler has been a director since 2016. Mr. Burgstahler is the President and Co-Managing Partner of Avista Capital Partners and is the Chief Executive Officer of Avista Healthcare Public Acquisition Corp. Mr. Burgstahler was a founding partner of Avista Capital Partners in 2005 and since 2009, has been President of Avista Capital Partners. Prior to forming Avista Capital Partners, Mr. Burgstahler was a partner of DLJ Merchant Banking Partners. Previously, Mr. Burgstahler worked at Andersen Consulting (now known as Accenture plc) and McDonnell Douglas (now known as The Boeing Company). Mr. Burgstahler currently serves as a director of Avista Healthcare Public Acquisition Corp., Inform Diagnostics, Inc., Kramer Laboratories, Inc., United BioSource Corporation and WideOpenWest, Inc. He is also a Trustee of the Trinity School in New York City. Mr. Burgstahler holds a B.S. in Aerospace Engineering from the University of Kansas and an M.B.A. from Harvard Business School.

Sriram Venkataraman

Sriram Venkataraman has been a director since 2016. He is a Partner of Avista Capital Partners, having joined in 2007. Prior to joining Avista Capital Partners, Mr. Venkataraman was a Vice President in the Healthcare Investment Banking group at Credit Suisse Group AG. Previously, he worked at GE Healthcare (formerly known as GE Medical Systems). He currently serves as a director of OptiNose, Inc., Inform Diagnostics, Inc. and National Spine & Pain Centers Holdings, LLC and previously served as a director of AngioDynamics, Inc., Lantheus Holdings, Inc. and Zest Anchors, Inc. Mr. Venkataraman holds an M.S. in Electrical Engineering from the University of Illinois, Urbana-Champaign and an M.B.A. from The Wharton School at the University of Pennsylvania.

Daniel Sielecki

Daniel Sielecki became a director of Osmotica Holdings Corp Ltd. in 2007 and joined the board of directors in 2016 in connection with the combination of Osmotica Holdings Corp Ltd. and Vertical/Trigen. Mr. Sielecki has worked at Laboratorios Phoenix S.A since 1975 and currently serves as a director of Simali S.A., Petroquımica Cuyo S.A and PEPCA S.A. He previously served as a director of Disprofarma S.A.

Carlos Sielecki

Carlos Sielecki became a director of Osmotica Holdings Corp Ltd. in 2007 and joined the board of directors in 2016 in connection with the combination of Osmotica Holdings Corp Ltd. and Vertical/Trigen. Mr. Sielecki currently serves as a director of Simali S.A. and holds a degree in architecture from the University of Buenos Aires.

Juan Vergez

Juan Vergez became a director in 2016. Mr. Vergez served as the President of Osmotica Argentina from November 2010 to May 2016, and as the New Business Director of Osmotica Argentina from May 2016 to December 2017. Mr. Vergez previously served as a director of Nutrifoods, S.A. and has more than 40 years of experience in the pharmaceutical industry.